Fundz
Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →

Synchron raised $200 million in Series D funding to support a pivotal trial for its brain-computer interface, aiming for FDA approval. This financing is crucial for launching its first-generation device.

PRIVATEJun 07, 2026•2 months ago

Amount Raised

$200 Million

Round Type

Series D

New YorkBiotechnologyHealth Care

Description

Synchron, the brain-computer interface company, raised $200 million in Series D financing aimed at funding a pivotal clinical trial in 2026. This trial is essential for obtaining FDA approval for its Stentrode implant. The company's goal is to commercialize its device to assist those living with severe paralysis. Success in this trial would position Synchron as the first company to file for permanent BCI approval.

Company Information

Company

Synchron

Location

New York, United States

About

Synchron is a clinical-stage endovascular brain computer interface (BCI) company. Since 2012, the company has been developing a BCI platform that avoids the need for open brain surgery by using a minimally-invasive procedure. The Synchron Switch™ BCI received FDA Breakthrough Device Designation in 2020, and is currently in human clinical trials in the US and Australia. Synchron has been published in multiple peer-reviewed journals including Nature Biotechnology, Nature Biomedical Engineering and JNIS. Synchron is based in Brooklyn, New York with R&D facilities in Melbourne, Australia. For more information, visit www.synchron.com. Follow us on Twitter @synchroninc.

Predictive Intelligence
Strategic

ML-powered predictions for Synchron's next move

Learn about Strategic plan

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals — including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications — based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include FundzWatch™ for automated website change detection, Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 200,000+ companies. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.